干燥综合征的诊治现状、挑战和思考

doi:10.16150/j.1671-2870.2022.03.001

摘要/Abstract

中图分类号:

R442.8

汤建平, 龚邦东. 干燥综合征的诊治现状、挑战和思考[J]. 诊断学理论与实践, 2022, 21(03): 291-298.

参考文献 40

[1]	Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjögren′s syndrome[J/OL]. Rheumato-logy(Oxford),2019-02-15. https://pubmed.ncbi.nlm.nih.gov/30770918/.
[2]	Jaskólska M, Chylińska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjögren′s syndrome: a preliminary report[J]. Rheumatol Int, 2020, 40(8):1267-1274. doi: 10.1007/s00296-020-04543-2 pmid: 32172462
[3]	Ramos-Casals M, Brito-Zerón P, Solans R, et al. Systemic involvement in primary Sjögren′s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)[J]. Rheumatology (Oxford), 2014, 53(2):321-331. doi: 10.1093/rheumatology/ket349 pmid: 24162151
[4]	Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren′s syndrome with topical and systemic therapies[J]. Ann Rheum Dis, 2020, 79(1):3-18. doi: 10.1136/annrheumdis-2019-216114 pmid: 31672775
[5]	张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59(4):269-276. pmid: 32209192
	Zhang W, Li XM, Xu D, et al. Recommendations of diagnosis and treatment of primary Sjögren′s syndrome in China[J]. Chin J Intern Med, 2020, 59(4):269-276. doi: 10.3760/cma.j.cn112138-20200113-00021 pmid: 32209192
[6]	Mariette X, Criswell LA. Primary Sjögren′s Syndrome[J]. N Engl J Med, 2018, 378(10):931-939. doi: 10.1056/NEJMcp1702514 URL
[7]	Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren′s syndrome: the JOQUER randomized clinical trial[J]. JAMA, 2014, 312(3):249-258. doi: 10.1001/jama.2014.7682 URL
[8]	van der Heijden EHM, Blokland SLM, Hillen MR, et al. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren′s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial[J]. Lancet Rheumatol, 2020, 2:e260-e269.
[9]	Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren′s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren′s Syndrome(TRIPSS)[J]. Arthritis Rheum, 2004, 50(4):1270-1276. doi: 10.1002/art.20146 URL
[10]	Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren′s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial[J]. Arthritis Rheum, 2004, 50(7):2240-2245. doi: 10.1002/art.20299 URL
[11]	Norheim KB, Harboe E, G? ransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren′s syndrome--a double blind, randomised clinical trial[J]. PLoS One, 2012, 7(1):e30123. doi: 10.1371/journal.pone.0030123 URL
[12]	Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren′s syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study[J]. Ann Rheum Dis, 2008, 67(11):1541-1544. doi: 10.1136/ard.2007.083865 pmid: 18276741
[13]	Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren′s syndrome: a randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheum, 2010, 62(4):960-968. doi: 10.1002/art.27314 URL
[14]	Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren′s syndrome with rituximab: a randomized trial[J]. Ann Intern Med, 2014, 160(4):233-242. pmid: 24727841
[15]	Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren′s syndrome[J]. Arthritis Rheumatol, 2017, 69(7):1440-1450. doi: 10.1002/art.40093 URL
[16]	Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren′s syndrome: results of the BELISS open-label phase Ⅱ study[J]. Ann Rheum Dis, 2015, 74(3):526-531. doi: 10.1136/annrheumdis-2013-203991 pmid: 24347569
[17]	Shao Q. Biologic therapy in Sjögren′s syndrome[J]. Clin Rheumatol, 2021, 40(6):2143-2154. doi: 10.1007/s10067-020-05429-1 pmid: 33106929
[18]	Theander E, Jonsson R, Sjöström B, et al. Prediction of Sjögren′s Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling[J]. Arthritis Rheumatol, 2015, 67(9):2427-2436. doi: 10.1002/art.39214 URL
[19]	Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis[J]. Autoimmun Rev, 2019, 18(1):93-106. doi: S1568-9972(18)30265-9 pmid: 30408582
[20]	Baldini C, Gallo A, Perez P, et al. Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren′s syndrome[J]. Clin Exp Rheumatol, 2012, 30(5):785-790. pmid: 23009763
[21]	Hall JC, Baer AN, Shah AA, et al. Molecular subsetting of interferon pathways in Sjögren′s syndrome[J]. Arthritis Rheumatol, 2015, 67(9):2437-2446. doi: 10.1002/art.39204 URL
[22]	Reale M, D′Angelo C, Costantini E, et al. MicroRNA in Sjögren′s Syndrome: their potential roles in pathogenesis and diagnosis[J]. J Immunol Res, 2018, 2018:7510174.
[23]	US National Library of Medicine. Safety and efficacy study of subcutaneous belimumab and intravenous ritu-ximab co-administration in Subjects with primary Sjögren′s syndrome[EB/OL]. 2020[2022-01-04]. https://clinicaltrials.gov/ct2/show/NCT02631538.
[24]	Dörner T, Posch MG, Li Y, et al. Treatment of primary Sjögren′s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity[J]. Ann Rheum Dis, 2019, 78(5):641-647. doi: 10.1136/annrheumdis-2018-214720 URL
[25]	Fisher BA, Szanto A, Ng AF, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren′s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study[J]. Lancet Rheumatol, 2020, 2:e142-e152.
[26]	Rivière E, Pascaud J, Tchitchek N, et al. Salivary gland epithelial cells from patients with Sjögren′s syndrome induce B-lymphocyte survival and activation[J]. Ann Rheum Dis, 2020, 79(11):1468-1477. doi: 10.1136/annrheumdis-2019-216588 pmid: 32843324
[27]	Juarez M, Diaz N, Johnston GI, et al. A phase 2 rando-mized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren′s syndrome[J]. Rheumatology (Oxford), 2021, 60(3):1364-1375. doi: 10.1093/rheumatology/keaa410 pmid: 32949140
[28]	Pitzalis C, Jones GW, Bombardieri M, et al. Ectopic lymphoid-like structures in infection, cancer and autoimmunity[J]. Nat Rev Immunol, 2014, 14(7):447-462. doi: 10.1038/nri3700 URL
[29]	St Clair EW, Baer AN, Wei C, et al. Clinical efficacy and safety of baminercept, a lymphotoxin β receptor fusion protein, in primary Sjögren′s syndrome: results from a phase Ⅱ randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol, 2018, 70(9):1470-1480. doi: 10.1002/art.40513 URL
[30]	Mariette X, Bombardieri M, Alevizos I, et al. A phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sjögren′s syndrome[J]. Arthritis Rheumatol, 2019, 71(Suppl 10):2417.
[31]	van Nimwegen JF, Mossel E, van Zuiden GS, et al. Abatacept treatment for patients with early active primary Sjögren′s syndrome: a single-centre, randomised, double-blind, placebocontrolled, phase 3 trial (ASAP-Ⅲ study)[J]. Lancet Rheumatol, 2020, 2:e153-e163.
[32]	Baer AN, Gottenberg JE, St Clair EW, et al. Efficacy and safety of abatacept in active primary Sjögren′s syndrome: results of a phase Ⅲ, randomised, placebo-controlled trial[J]. Ann Rheum Dis, 2021, 80(3):339-348. doi: 10.1136/annrheumdis-2020-218599 URL
[33]	US National Library of Medicine. Safety of tofacitinib, an oral janus kinase inhibitor, in primary Sjögren′s syndrome[EB/OL].2021[2022-01-04]. https://clinicaltrials.gov/ct2/show/NCT04496960.
[34]	US National Library of Medicine. Pilot Trial of Usteki-numab for Primary Sjögren′s Syndrome[EB/OL]. 2021[2022-01-04]. https://clinicaltrials.gov/ct2/show/NCT04093531.
[35]	Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren′s syndrome[J]. Blood, 2012, 120(15):3142-3151.
[36]	Gong B, Zheng L, Lu Z, et al. Mesenchymal stem cells negatively regulate CD4 + T cell activation in patients with primary Sjögren′s syndrome through the miRNA-125b and miRNA-155 TCR pathway[J]. Mol Med Rep, 2021, 23(1):43.
[37]	Gong B, Zheng L, Huang W, et al. Murine embryonic mesenchymal stem cells attenuated xerostomia in Sjögren′s-like mice via improving salivary gland epithelial cell structure and secretory function[J]. Int J Clin Exp Pathol, 2020, 13(5):954-963.
[38]	Oni C, Mitchell S, James K, et al. Eligibility for clinical trials in primary Sjögren′s syndrome: lessons from the UK Primary Sjögren′s Syndrome Registry[J]. Rheumatology (Oxford), 2016, 55(3):544-552.
[39]	Devauchelle-Pensec V, Gottenberg JE, Jousse-Joulin S, et al. Which and how many patients should be included in randomised controlled trials to demonstrate the efficacy of biologics in primary Sjögren′s syndrome?[J]. PLoS One, 2015, 10(9):e0133907. doi: 10.1371/journal.pone.0133907 URL
[40]	Arends S, Wolff LD, Nimwegen JV, et al. Composite of relevant endpoints for Sjögren′s syndrome(CRESS)[J]. Arthritis Rheumatol, 2020, 72(Suppl 10):1502.

干燥综合征的诊治现状、挑战和思考

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 8

编辑推荐

Metrics

本文评价

[1]	陆弘逾, 顾俊, 王静, 曹亚峰, 宋陆茜, 范俊, 陈梅. 干燥综合征继发隐球菌性脑膜脑炎一例报告及相关自身免疫病文献复习[J]. 诊断学理论与实践, 2021, 20(05): 456-461.
[2]	赵茜, 赵肖庆, 刁立诚, 孙菲, 郑捷, 朱雪梅, 曹华. 伴皮肤紫癜的原发性干燥综合征患者的临床特征分析[J]. 诊断学理论与实践, 2021, 20(02): 155-160.
[3]	史玉玲. 英国《皮肤科医师协会银屑病生物制剂治疗指南》（2020版）解读[J]. 诊断学理论与实践, 2021, 20(01): 37-42.
[4]	王艳青, 黄琬雪, 梁媛媛, 吴珍珍, 王璇, 汤建平. 原发性干燥综合征患者合并周围神经病变的临床及实验室特点分析[J]. 诊断学理论与实践, 2019, 18(1): 51-55.
[5]	梁媛媛, 王璇, 汤建平. 干燥综合征合并肺间质病变的临床诊断治疗进展[J]. 诊断学理论与实践, 2018, 17(05): 606-610.
[6]	龚邦东, 汤建平. 干燥综合征分类标准的时代演化及对临床诊断的指导价值[J]. 诊断学理论与实践, 2018, 17(03): 244-248.
[7]	刘维超, 王苏丽, 陈盛, 林艳伟, 吕良敬,. 干燥综合征合并神经系统损害、抗利尿激素分泌异常综合征一例报告[J]. 诊断学理论与实践, 2016, 15(03): 331-332.
[8]	顾寒英, 施若非, 陈迎春, 王刚,. 干燥综合征合并中枢神经系统脱髓鞘疾病的临床特点分析[J]. 诊断学理论与实践, 2014, 13(01): 86-89.